
Stacey-Lynn Paiva

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5573149/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dumping STAT3 in the trash. Nature Reviews Drug Discovery, 2020, 19, 19-19.	21.5	1
2	Learning from worms to kill Gram-negative bacteria. Nature Reviews Drug Discovery, 2020, 19, 22-22.	21.5	0
3	Widening the window of bromodomain inhibition. Nature Reviews Drug Discovery, 2020, 19, 166-166.	21.5	0
4	Saving hearts with HDAC inhibition. Nature Reviews Drug Discovery, 2020, 19, 92-92.	21.5	2
5	Tapping the therapeutic potential of the innate immune system. Nature Reviews Drug Discovery, 2020, 19, 236-236.	21.5	0
6	Targeted Protein Internalization and Degradation by ENDosome TArgeting Chimeras (ENDTACs). ACS Central Science, 2019, 5, 1079-1084.	5.3	26
7	Targeted protein degradation: elements of PROTAC design. Current Opinion in Chemical Biology, 2019, 50, 111-119.	2.8	363
8	Building a designer cytokine to treat type 2 diabetes. Nature Reviews Drug Discovery, 2019, 18, 825-825.	21.5	0
9	Adding to the senolytic arsenal. Nature Reviews Drug Discovery, 2019, 18, 901-901.	21.5	3
10	Avoiding target misidentification. Nature Reviews Drug Discovery, 2019, 18, 826-826.	21.5	2
11	Regulating the Master Regulator: Controlling Ubiquitination by Thinking Outside the Active Site. Journal of Medicinal Chemistry, 2018, 61, 405-421.	2.9	9
12	A selective inhibitor of the UFM1-activating enzyme, UBA5. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4542-4547.	1.0	17
13	Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells. PLoS ONE, 2014, 9, e93530.	1.1	31
14	Exploring a New Frontier in Cancer Treatment: Targeting the Ubiquitin and Ubiquitin-like Activating Enzymes. Journal of Medicinal Chemistry, 2013, 56, 2165-2177.	2.9	27
15	Targeting the Ubiquitin E1 as a Novel Anti-Cancer Strategy. Current Pharmaceutical Design, 2013, 19, 3201-3209.	0.9	22